Quadrant Private Wealth Management, LLC - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 102 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q2 2022. The put-call ratio across all filers is 0.07 and the average weighting 0.1%.

Quarter-by-quarter ownership
Quadrant Private Wealth Management, LLC ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q2 2024$9,973
-55.1%
10,000
-33.3%
0.00%
-66.7%
Q1 2024$22,200
+103.7%
15,000
+50.0%
0.01%
+100.0%
Q4 2023$10,900
-7.6%
10,0000.0%0.00%
-25.0%
Q3 2023$11,800
-16.3%
10,0000.0%0.00%0.0%
Q2 2023$14,100
-6.0%
10,0000.0%0.00%
-20.0%
Q1 2023$15,000
+28.2%
10,0000.0%0.01%
+25.0%
Q4 2022$11,700
-26.9%
10,0000.0%0.00%
-42.9%
Q2 2022$16,000
+6.7%
10,0000.0%0.01%
+16.7%
Q1 2022$15,000
-40.0%
10,0000.0%0.01%
-33.3%
Q4 2021$25,0000.0%10,0000.0%0.01%
-10.0%
Q3 2021$25,000
-13.8%
10,0000.0%0.01%
-16.7%
Q2 2021$29,000
+20.8%
10,0000.0%0.01%
+20.0%
Q1 2021$24,000
+33.3%
10,0000.0%0.01%
+25.0%
Q4 2020$18,000
+100.0%
10,0000.0%0.01%
+60.0%
Q3 2020$9,0000.0%10,0000.0%0.01%0.0%
Q2 2020$9,000
+12.5%
10,0000.0%0.01%
-28.6%
Q1 2020$8,000
-11.1%
10,0000.0%0.01%
-12.5%
Q4 2019$9,00010,0000.01%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q2 2022
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$52,403,2283.69%
Raffles Associates 1,536,946$2,305,4193.14%
Defender Capital, LLC. 5,136,085$7,704,1282.69%
Prescott General Partners LLC 1,851,851$2,777,7770.22%
DAFNA Capital Management LLC 140,000$210,0000.06%
Beirne Wealth Consulting Services, LLC 45,000$67,5000.05%
CTC Capital Management, LLC 14,100$21,1500.04%
Diametric Capital, LP 50,875$76,3130.04%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 781,766$1,172,6490.03%
One68 Global Capital, LLC 13,377$20,0660.03%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders